Otivio AS
10
1
1
3
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 85/100
20.0%
2 terminated/withdrawn out of 10 trials
60.0%
-26.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 3 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (10)
Intermittent Negative Pressure for Patients With Diabetic Foot Ulcers (INPRESS) Study
Role: collaborator
Performance and Long-term Safety of FlowOx2.0™ in Patients With Multiple Sclerosis - Impact on Spasticity and Pain
Role: lead
Performance and Long-term Safety of FlowOx2.0™, Multiple Sclerosis, Spasticity and Pain
Role: lead
Pilot Investigation to Evaluate FlowOx2.0™ for Experimental Treatment of Spasticity
Role: lead
Intermittent Negative Pressure; Impact on Peripheral Artery Disease and Intermittent Claudication
Role: lead
Intermittent Negative Pressure to Improve Blood Flow in Patients With Peripheral Artery Disease: Effects After Long-term Treatment
Role: collaborator
Intermittent Negative Pressure to Improve Blood Flow in Patients With Peripheral Artery Disease: Optimal Pulse Pressure Regime
Role: collaborator
The Effects of Intermittent Negative Pressure on Wound Healing and Peripheral Circulation in Spinal Cord Injured Subjects
Role: collaborator
The Effects of INP on Peripheral Circulation in Dialysis Patients and Patients With PAD and Leg Ulcers
Role: collaborator
Effect on Blood Flow Using the FlowOx™ Device in Patients With Reduced Peripheral Circulation in the Lower Leg
Role: lead
All 10 trials loaded